Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Jan 2019
Historique:
received: 14 11 2018
revised: 14 12 2018
accepted: 08 01 2019
entrez: 17 1 2019
pubmed: 17 1 2019
medline: 25 4 2019
Statut: epublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western countries, with a continuously rising incidence. Gut-liver communication and microbiota composition have been identified as critical drivers of the NAFLD progression. Hence, it has been shown that microbiota depletion can ameliorate high-fat diet or western-diet induced experimental Non-alcoholic steatohepatitis (NASH). However, its functional implications in the methionine-choline dietary model, remain incompletely understood. Here, we investigated the physiological relevance of gut microbiota in methionine-choline deficient (MCD) diet induced NASH. Experimental liver disease was induced by 8 weeks of MCD feeding in wild-type (WT) mice, either with or without commensal microbiota depletion, by continuous broad-spectrum antibiotic (AB) treatment. MCD diet induced steatohepatitis was accompanied by a reduced gut microbiota diversity, indicating intestinal dysbiosis. MCD treatment prompted macroscopic shortening of the intestine, as well as intestinal villi in histology. However, gut microbiota composition of MCD-treated mice, neither resembled human NASH, nor did it augment the intestinal barrier integrity or intestinal inflammation. In the MCD model, AB treatment resulted in increased steatohepatitis activity, compared to microbiota proficient control mice. This phenotype was driven by pronounced neutrophil infiltration, while AB treatment only slightly increased monocyte-derived macrophages (MoMF) abundance. Our data demonstrated the differential role of gut microbiota, during steatohepatitis development. In the context of MCD induced steatohepatitis, commensal microbiota was found to be hepatoprotective.

Identifiants

pubmed: 30646522
pii: ijms20020308
doi: 10.3390/ijms20020308
pmc: PMC6358781
pii:
doi:

Substances chimiques

Methionine AE28F7PNPL
Choline N91BDP6H0X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : TR 285/10-1
Organisme : Bundesministerium für Bildung und Forschung
ID : ObiHep grant #01KU1214A
Organisme : Bundesministerium für Bildung und Forschung
ID : LiSyM (CT)
Organisme : Bundesministerium für Bildung und Forschung
ID : HDHL-INTIMIC Di-Mi-Liv

Références

Gut. 2001 Feb;48(2):206-11
pubmed: 11156641
Alcohol Clin Exp Res. 2005 Nov;29(11 Suppl):140S-145S
pubmed: 16344599
J Lipid Res. 2006 Oct;47(10):2280-90
pubmed: 16829692
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):979-84
pubmed: 17210919
Diabetologia. 2007 Jun;50(6):1267-76
pubmed: 17426960
J Lipid Res. 2008 May;49(5):1068-76
pubmed: 18227531
J Hepatol. 2008 Jun;48(6):983-92
pubmed: 18395289
Curr Opin Lipidol. 2008 Jun;19(3):229-34
pubmed: 18460912
Hepatology. 2009 Mar;49(3):989-97
pubmed: 19115316
Hepatology. 2009 Jun;49(6):1877-87
pubmed: 19291785
FASEB J. 2010 Mar;24(3):731-9
pubmed: 19841034
Hepatology. 2010 Feb;51(2):679-89
pubmed: 20041406
Gastroenterology. 2010 Jul;139(1):323-34.e7
pubmed: 20347818
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Biol Chem. 2010 Jun 11;285(24):18528-36
pubmed: 20395294
Diabetologia. 2010 Aug;53(8):1795-806
pubmed: 20407745
BMC Gastroenterol. 2010 May 28;10:52
pubmed: 20509914
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
Am J Physiol Gastrointest Liver Physiol. 2011 Mar;300(3):G433-41
pubmed: 21233280
Hepatology. 2011 Mar;53(3):810-20
pubmed: 21319198
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
Nature. 2012 Feb 01;482(7384):179-85
pubmed: 22297845
Dig Dis Sci. 2012 Jul;57(7):1932-41
pubmed: 22427130
Cancer Cell. 2012 Apr 17;21(4):504-16
pubmed: 22516259
PLoS One. 2012;7(12):e52411
pubmed: 23285030
Hepatology. 2013 Jun;57(6):2189-201
pubmed: 23339067
Curr Pharm Des. 2013;19(29):5250-69
pubmed: 23394092
Curr Opin Gastroenterol. 2013 May;29(3):264-70
pubmed: 23493073
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):627-36
pubmed: 23958599
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65
pubmed: 24080776
Gastroenterology. 2014 May;146(6):1513-24
pubmed: 24440671
J Hepatol. 2014 Oct;61(4):883-90
pubmed: 24845607
World J Gastroenterol. 2014 Jun 21;20(23):7381-91
pubmed: 24966608
Frontline Gastroenterol. 2014 Jul;5(3):211-218
pubmed: 25018867
FASEB J. 2015 Mar;29(3):1043-55
pubmed: 25466902
Lab Anim. 2015 Apr;49(1 Suppl):47-58
pubmed: 25835738
PLoS One. 2015 May 27;10(5):e0127991
pubmed: 26017539
Hepatology. 2015 Nov;62(5):1405-16
pubmed: 26178698
Semin Liver Dis. 2015 Aug;35(3):221-35
pubmed: 26378640
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Dig Dis Sci. 2016 May;61(5):1294-303
pubmed: 26841783
Lipids Health Dis. 2016 Jun 18;15:108
pubmed: 27317359
Blood. 2017 Feb 9;129(6):729-739
pubmed: 27879260
Cell Mol Gastroenterol Hepatol. 2016 May 05;2(5):584-604
pubmed: 28090564
Curr Opin Gastroenterol. 2017 May;33(3):128-133
pubmed: 28257306
Nat Rev Immunol. 2017 Apr;17(4):219-232
pubmed: 28260787
J Hepatol. 2017 Jun;66(6):1300-1312
pubmed: 28267621
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
Hepatology. 2018 May;67(5):1754-1767
pubmed: 28833331
Nutrients. 2017 Sep 14;9(9):null
pubmed: 28906444
J Clin Transl Hepatol. 2017 Sep 28;5(3):216-223
pubmed: 28936403
Hepatology. 2018 Apr;67(4):1270-1283
pubmed: 28940700
J Hepatol. 2018 May;68(5):1083-1085
pubmed: 29519549
Cell Mol Gastroenterol Hepatol. 2018 Jan 08;5(3):399-413
pubmed: 29552626
Nat Commun. 2018 Jul 20;9(1):2872
pubmed: 30030441

Auteurs

Kai Markus Schneider (KM)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. Kai.Markus.Schneider@gmail.com.

Antje Mohs (A)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. amohs@ukaachen.de.

Konrad Kilic (K)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. konrad.kilic@gmail.com.

Lena Susanna Candels (LS)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. lcandels@ukaachen.de.

Carsten Elfers (C)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. celfers@ukaachen.de.

Eveline Bennek (E)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. ebennek@ukaachen.de.

Lukas Ben Schneider (LB)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. Lukas.Ben.Schneider@gmx.de.

Felix Heymann (F)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. fheymann@ukaachen.de.

Nikolaus Gassler (N)

Department of Pathology, Klinikum Braunschweig, 38118 Braunschweig, Germany. n.gassler@klinikum-braunschweig.de.

John Penders (J)

Department of Medical Microbiology, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands. j.penders@maastrichtuniversity.nl.

Christian Trautwein (C)

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. ctrautwein@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH